Dose-intensive cyclophosphamide, etoposide, cisplatin reinduction for relapsed/refractory aggressive non-Hodgkin lymphoma (r/r-aNHL).

Jan-Willem Henning,Qiuli Duan,Nizar J. Bahlis,Andrew Daly,Peter Duggan,Mona Shafey,Douglas A. Stewart

Dose-intensive cyclophosphamide, etoposide, cisplatin reinduction for relapsed/refractory aggressive non-Hodgkin lymphoma (r/r-aNHL).

2017

Jan-Willem Henning
Qiuli Duan
Nizar J. Bahlis
Andrew Daly
Peter Duggan
Mona Shafey
Douglas A. Stewart

6548 Background: Approximately 2/3 r/r-aNHL patients (pts) respond to salvage R-ICE or R-DHAP, 1/2 proceed to autologous stem cell transplantation (ASCT), and 1/3 achieve 3 year (yr) progression-fr...

Keywords:

Refractory
Oncology
Pathology
Cisplatin
Cyclophosphamide/Etoposide
Autologous stem-cell transplantation
Aggressive Non-Hodgkin Lymphoma
Medicine
Internal medicine
relapsed refractory

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations